In Depth Partners LLC Has $2.98 Million Holdings in Zoetis Inc. (NYSE:ZTS)

In Depth Partners LLC lowered its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 45.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,274 shares of the company's stock after selling 15,454 shares during the quarter. Zoetis accounts for about 3.2% of In Depth Partners LLC's holdings, making the stock its 11th largest position. In Depth Partners LLC's holdings in Zoetis were worth $2,977,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC grew its stake in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. increased its stake in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after buying an additional 166 shares in the last quarter. Murphy & Mullick Capital Management Corp bought a new position in shares of Zoetis in the fourth quarter worth about $44,000. Asset Planning Inc acquired a new stake in shares of Zoetis in the 4th quarter valued at $58,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in Zoetis in the fourth quarter worth about $59,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on ZTS. Piper Sandler upped their target price on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. Stifel Nicolaus reduced their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. Morgan Stanley decreased their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $214.40.

Insider Buying and Selling at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company's stock, valued at $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Stock Performance

Shares of Zoetis stock traded up $1.28 on Friday, hitting $153.58. The stock had a trading volume of 3,543,605 shares, compared to its average volume of 2,512,294. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The stock has a market cap of $68.52 billion, a price-to-earnings ratio of 28.08, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. The business's 50 day moving average is $158.96 and its two-hundred day moving average is $168.86.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.30%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is presently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.